source
- VectorY Therapeutics raises $83.5M Series A to develop brain-targeted antibody gene therapyVectorY Therapeutics announced it has closed a Series A financing round, adding €74.5 million ($83.5 million) to its capital. The funds will be used to advance its lead gene-therapy candidate VTx-…
- Flagship-backed Valo Health merges with Montai Therapeutics to boost AI-driven drug pipelineValo Health and Montai Therapeutics announced they will combine under the Valo brand, creating a larger AI-focused biotech aimed at accelerating early-stage drug discovery. Valo, launched in 2020…